Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H31NO2S |
| Molecular Weight | 349.531 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(OCCN1CCCCCC1)C(C2CCCCC2)C3=CSC=C3
InChI
InChIKey=MMNICIJVQJJHHF-UHFFFAOYSA-N
InChI=1S/C20H31NO2S/c22-20(23-14-13-21-11-6-1-2-7-12-21)19(18-10-15-24-16-18)17-8-4-3-5-9-17/h10,15-17,19H,1-9,11-14H2
| Molecular Formula | C20H31NO2S |
| Molecular Weight | 349.531 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Cetiedil is effective potassium channel blocker used as a peripheral vasodilator to treat patients with painful crises in sickle cell anemia and pain in the extremities caused by an arterial disease. Known pharmacological properties of the drug include vascular smooth muscle relaxation, inhibition of phosphodiesterase with the consequent increase in circulating cyclic AMP concentration, blockade of the effect of bradykinin and serotonin, analgesia, inhibition of platelet aggregation and the decrease of plasma and blood viscosity and plasma fibrinogen level. The antisickling effect of cetiedil is explained mainly in the light of the changes it induces in the activities of membrane-bound ATPases and the permeability properties of the erythrocyte membrane to cations and anions.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacology of the human red cell voltage-dependent cation channel; Part I. Activation by clotrimazole and analogues. | 2004-01-22 |
|
| Inhibition of the antigen-induced activation of RBL-2H3 cells by cetiedil and some of its analogues. | 2004-01-12 |
|
| Inhibition of the antigen-induced activation of RBL-2H3 cells by charybdotoxin and cetiedil. | 2004-01-12 |
|
| An analysis of the mechanism by which cetiedil inhibits sickling. | 2002-01-18 |
|
| Synthesis and structure-activity relationships of cetiedil analogues as blockers of the Ca(2+)-activated K+ permeability of erythrocytes. | 2001-09-27 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:40:11 GMT 2025
by
admin
on
Mon Mar 31 18:40:11 GMT 2025
|
| Record UNII |
621RT200TO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QC04AX26
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
||
|
WHO-ATC |
C04AX26
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
14176-10-4
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
SUB07450MIG
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
621RT200TO
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
3171
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
66384
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
238-028-2
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
DB13753
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
580
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
C79584
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
CHEMBL419380
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
20609
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | RxNorm | ||
|
m3289
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | Merck Index | ||
|
CETIEDIL
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
DTXSID70864474
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
100000081512
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY | |||
|
C006955
Created by
admin on Mon Mar 31 18:40:11 GMT 2025 , Edited by admin on Mon Mar 31 18:40:11 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |